Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease

Autor: Salvatore P. Costa, Mandeep S. Sidhu, Robert S. Rosenson, Sripal Bangalore, Roy O. Mathew, Radmila Lyubarova, Rafia I Chaudhry
Rok vydání: 2020
Předmět:
0301 basic medicine
medicine.medical_specialty
medicine.medical_treatment
Population
Hyperlipidemias
030204 cardiovascular system & hematology
urologic and male genital diseases
Niacin
End stage renal disease
03 medical and health sciences
0302 clinical medicine
Ezetimibe
Renal Dialysis
Risk Factors
Internal medicine
Hyperlipidemia
medicine
Humans
Pharmacology (medical)
Renal Insufficiency
Chronic
education
Dialysis
Hypolipidemic Agents
Randomized Controlled Trials as Topic
Pharmacology
education.field_of_study
business.industry
PCSK9 Inhibitors
Fibric Acids
Patient Acuity
General Medicine
Atherosclerosis
medicine.disease
Lipids
female genital diseases and pregnancy complications
Clinical trial
030104 developmental biology
Practice Guidelines as Topic
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proprotein Convertase 9
Cardiology and Cardiovascular Medicine
business
Dyslipidemia
Glomerular Filtration Rate
Kidney disease
medicine.drug
Zdroj: Cardiovascular Drugs and Therapy. 35:479-489
ISSN: 1573-7241
0920-3206
Popis: Atherosclerotic cardiovascular disease (ASCVD) remains an important contributor of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is recognized as an important risk enhancer that identifies patients as candidates for more intensive low-density lipoprotein (LDL) cholesterol lowering. However, there is controversy regarding the efficacy of lipid-lowering therapy, especially in patients on dialysis. Among patients with CKD, not yet on dialysis, there is clinical trial evidence for the use of statins with or without ezetimibe to reduce ASCVD events. Newer cholesterol lowering agents have been introduced for the management of hyperlipidemia to reduce ASCVD, but these therapies have not been tested in the CKD population except in secondary analyses of patients with primarily CKD stage 3. This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population.
Databáze: OpenAIRE
Externí odkaz: